EPZM News and Press, Epizyme Inc. From 02/14/21

Today, we do a deep dive on Epizyme for the first time since March of last year. The stock is one of the few in the market near its 52-week lows.  The name has become a 'battleground stock' among analysts as well. What is ahead for Epizyme in 2021?  We try to answer that...

Jaguar Health (JAGX) -16%.Foresight Autonomous Holdings (FRSX) -12%.Altimmune (ALT) -10% after FDA places hold on Altimmune's IND for COVID-19 vaccine candidate.Alibaba Group Holding (BABA) -9% after anti-monopoly probe by China.Aqua Metals (AQMS) -9%.Ocugen (OCGN)&#x...

Epizyme (EPZM) said Boehringer Ingelheim International ((BII)) has elected to terminate a collaboration agreement between both the companies, without providing any cause for the termination, effective January 31.Under the agreement, the parties had agreed to discover, research, develop and co...

Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will participate in a fireside chat during the Jefferies Virtua...

Image source: The Motley Fool. Epizyme Inc (NASDAQ: EPZM) Q3 2020 Earnings Call Nov 6, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Epizyme Inc (EPZM) Q3 2020 Earnings Call Transcript

Epizyme, Inc. (EPZM) Q3 2020 Results Earnings Conference Call November 6, 2020, 08:00 AM ET Company Participants Alicia Davis - Investor Relations, THRUST Strategic Communications Robert Bazemore - President and Chief Executive Officer Matthew Ros - Executive Vice President, Chief Strategy an...

Gainers: Aurora Cannabis (ACB) +82%, Sundial Growers (SNDL) +69%, Tilray (TLRY) +36%, OrganiGram Holdings Inc. (OGI) +30%, MEDNAX (MD) +19%.Losers: Assembly Biosciences (ASMB) -69%, Global Blood Therapeutics (GBT) -35%, AcelRx Pharmaceuti...

Epizyme ([[EPZM]] -23.2%) Q3 results:Revenue of $3.57M (-37.6% Y/Y) vs consensus of $5.9MNet loss: ($56.1M) (+4.1%); loss/share: ($0.55) (+5.2%); Quick Assets: $279.9M.Financial Guidance: Epizyme expects that its existing cash and equivalents will fund the company’s operations int...

Assembly Biosciences (ASMB) -55% on Q3 earnings release.Global Blood Therapeutics (GBT) -32% on Q3 earnings release.Epizyme (EPZM) -23% on Q3 earnings release.Marin Software (MRIN) -14% on Q3 earnings release.Hall of Fame Resort & Entertainment (HOF...

Epizyme (EPZM): Q3 GAAP EPS of -$0.55 beats by $0.06.Revenue of $3.57M (-37.6% Y/Y) misses by $2.32M.Press Release For further details see: Epizyme EPS beats by $0.06, misses on revenue